Arecor Therapeutics

Specialty Hospital products formulation collaboration

Lighthouse | 10 November 2022

Share this note

  • Arecor has struck an exclusive Specialty Hospital product formulation study collaboration with a new, but un-named, partner. The deal is with the pharmaceutical division of one of the largest global chemicals and pharmaceuticals companies that, importantly, is focused on the development and commercialisation of such specialty products.
  • Arecor’s proprietary Arestat formulation technology will be used to create a novel, and differentiated, formulation of an intravenous injectable drug. The aim is to create a stable and convenient Ready to Use (RTU) product that eliminates the need for reconstitution prior to administration. RTU products are clinically appealing given the time saving element (numerous studies have shown staff time savings comfortably justify even material price premiums), and, more importantly, the simpler handling which materially reduces dispensing and administration errors.
  • The undisclosed partner will fund the development work and, once the formulation is delivered, it has the option to acquire the rights and associated intellectual property to allow further development and commercialisation of the product. As described in previous notes, such collaborations are immediately revenue generating through research fees. If the option is exercised, the licensing deal will likely, in line with Arecor’s existing pre-licence technology partnerships, include clinical and commercial milestones and net sales royalties or equivalent.
  • Arecor has created a portfolio of partnered and in-house assets with improved properties through application of the Arestat technology to develop novel formulations of existing drugs with enhanced properties that would otherwise be challenging to achieve. These properties range from improved stability (extending the shelf-life of protein products), to altered supply chain requirements (greater temperature stability eliminating the need for cold chains), to conversion of lyophilised powders to stable RTU liquid dose forms (for faster and safer use), to improved therapeutic profiles (impacting patient outcomes and quality of life). Once commercialised, products derived from technology collaborations will provide a stream of recurring royalty-based revenues.

Trinity Delta view: This collaboration is a valuable reminder of the importance of Arecor’s Specialty Hospital products business and the applicability of its Arestat technology platforms in assisting larger, often blue chip, companies in addressing varied formulation challenges. The clinical and commercial potential of its diabetes franchise has focussed investor attention on development progress of AT278 (ultra-rapid ultra-concentrated insulin) and AT247 (ultra-rapid insulin), and so it is easy to overlook the value inherent in such Specialty Hospital products. The current pipeline includes two Specialty Hospital products licensed to Hikma, while disclosed formulation development partners include Lilly, Par Pharma, and Intas. Collectively the known Specialty Hospital product assets represent £75.2m (246.1p per share) of our £177.1m (580.9p per share) rNPV-based valuation.


10 November 2022

Market Cap£71.6m
Primary exchangeAIM London
Company CodeAREC
Corporate clientYes

Company description

Arecor Therapeutics is a revenue-generating clinical stage drug developer, with a well-balanced portfolio of in-house and partnered programmes. Its proprietary Arestat formulation platforms result in enhanced products with lower development risks and less onerous regulatory approvals.


Lala Gregorek
+44 (0) 20 3637 5043

Philippa Gardner
+44 (0) 20 3637 5042


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2022 Trinity Delta Research Limited. All rights reserved.